Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 14;14(1):3718.
doi: 10.1038/s41598-023-50677-1.

Apela promotes blood vessel regeneration and remodeling in zebrafish

Affiliations

Apela promotes blood vessel regeneration and remodeling in zebrafish

Nicolas Nys et al. Sci Rep. .

Abstract

In contrast to adult mammals, zebrafish display a high capacity to heal injuries and repair damage to various organs. One of the earliest responses to injury in adult zebrafish is revascularization, followed by tissue morphogenesis. Tissue vascularization entails the formation of a blood vessel plexus that remodels into arteries and veins. The mechanisms that coordinate these processes during vessel regeneration are poorly understood. Hence, investigating and identifying the factors that promote revascularization and vessel remodeling have great therapeutic potential. Here, we revealed that fin vessel remodeling critically depends on Apela peptide. We found that Apela selectively accumulated in newly formed zebrafish fin tissue and vessels. The temporal expression of Apela, Apln, and their receptor Aplnr is different during the regenerative process. While morpholino-mediated knockdown of Apela (Mo-Apela) prevented vessel remodeling, exogenous Apela peptide mediated plexus repression and the development of arteries in regenerated fins. In contrast, Apela enhanced subintestinal venous plexus formation (SIVP). The use of sunitinib completely inhibited vascular plexus formation in zebrafish, which was not prevented by exogenous application. Furthermore, Apela regulates the expression of vessel remolding-related genes including VWF, IGFPB3, ESM1, VEGFR2, Apln, and Aplnr, thereby linking Apela to the vascular plexus factor network as generated by the STRING online database. Together, our findings reveal a new role for Apela in vessel regeneration and remodeling in fin zebrafish and provide a framework for further understanding the cellular and molecular mechanisms involved in vessel regeneration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Apela is upregulated during zebrafish caudal fin regeneration. (A) Schematic representation of experimental plan showing amputation site and regenerated fin areas. Adult zebrafish were anesthetized in tricaine and fins were amputated and allowed to regenerate for indicated time periods. (B) Total RNA was isolated from fins (15–20 fins per time point) with uncut fins as controls (0 dpa) and analyzed by real-time PCR using specific primers for Apela or β-actin. Results are shown in the bar graph and are expressed as the ratio of the indicated transcripts relative to control (0 dpa). Results are shown as means ± S.E. of three experiments performed in triplicate. (C) Representative confocal images of control fins (0 dpa) and at 3 dpa (n = 12) subjected to immunofluorescence of Apela (red signal). (D) Quantification of fluorescence intensity in ImageJ. (E) Total RNA was isolated from fins (15–20 fins per time point) with uncut fins as controls (0 dpa) and analyzed by real-time PCR as in (A), using specific primers for Apln. (F) Aplnra and Aplnrb expression analysis by RT-PCR in uncut fins. (G) Aplnra expression analysis as in (A). The mean ± S.E values are shown. *p < 0.05. Scale bars represent 0.5 mm.
Figure 2
Figure 2
Blockade of Apela expression suppresses vessel differentiation. (A, B) Representative confocal images of caudal fins of adult zebrafish (15–20 fins/per experiment) that were electroporated with control Mo-CTL and Mo directed against Apela (Mo-Apela), and fin were allowed to regenerate for 3 days prior Apela expression analysis by immunohistochemistry using an anti-Apela. (C, D) MO-Apela had no effect on total fin regeneration. (E) Schematic representation of anastomotic bridge with emerging sprouts forming vascular plexus and the U-shaped formed by the artery and the two veins. (F) Inhibition of Apela by MO-Apela prevents remodeling of immature vascular network during fin regenerating in Tg(fli:EGFP)y, as observed with the enhanced plexus (G) and branching (H) vasculature. Results are shown as means ± S.E. of three experiments performed in triplicate. *p < 0.05. NS, not significant.
Figure 3
Figure 3
Apela mediates fin vessel differentiation during regeneration. (A, B) Tg(fli:EGFP)y1 zebrafish exposed to Apela (10 μM) after fin amputation and were allowed to regenerate prior analysis. (C, E) Tg(fli:EGFP)y1 fins (20 fins/per experiment) treatment with Apela (10 μM) shows reduced vasculature plexus (D) and branching (E). (F, G) Western blot analysis of the activation of AKT in control fins and after 15 min treatment with Apela (10 μM). Images shown in upper and lower panels were cropped from the same blot. Full blots are provided in Supplementary Fig. 1. All results shown are representative of at least 3 independent experiments with means ± S.E and *p < 0.05.
Figure 4
Figure 4
Sunitinib and Apela cross talk during vascular plexus regeneration and remodeling. (A) Zebrafish (15–20/per experiment) exposed to Sunitinib (0.5 μM) in the absence and presence of Apela (10 μM) after fin amputation and allowed to regenerate during 3 days prior analysis. (B) Results are shown as means ± S.E. of three experiments performed in triplicate. *p < 0.05.
Figure 5
Figure 5
Apela and vascular plexus remodeling molecule network. (A) The STRING network view. Combined screenshots from the STRING website, which has been queried with a subset of proteins involved in the formation and remodeling of vascular vessels (Notch, VEGF, Ephrin, Hedgehog, TGF, COUP-TFII, FOXC2 and others. Colored lines between the proteins indicate the interaction evidence. (B, C) Relative expression of indicated VWF, IGFPB3, ESM1, VEGFR2, Apela, Apln and Aplnr mRNA in pooled fin zebrafish (15–20/per experiment) treated with Apela (B) or Mo-Apela (C). (D) STRING network queried with the same subset of proteins in (A) and the set of the angiogenic proteins: VWF, IGFPB3, ESM1, VEGFR2, Apela, Apln and Aplnr. Red lines between the proteins indicate the new interaction evidence. For (B) and (C), results are shown as means ± S.E. of three experiments performed in triplicate. *p < 0.05.
Figure 6
Figure 6
Effect of Apela on sub-intestinal venous plexus (SIVP) formation. (AC) Tg(fli:EGFP)y1 embryos zebrafish (15–20/per experiment) were treated with Apela and sunitinib (for comparison) and the number of SIV compartments (B) and tip cells (C) were enumerated. Yellow arrowheads point to compartments. (D) Injection of MO-Apela into zebrafish embryos at the 1–4 cell stage, significantly affected normal embryonic development. For (B) and (C), results are shown as means ± S.E. of three experiments performed in triplicate. *p < 0.05.

Similar articles

Cited by

References

    1. Herbert SP, Stainier DYR. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 2011;12:551–564. doi: 10.1038/nrm3176. - DOI - PMC - PubMed
    1. Wacker A, Gerhardt H. Endothelial development taking shape. Curr. Opin. Cell Biol. 2011;23:676–685. - PubMed
    1. DiPietro LA. Angiogenesis and scar formation in healing wounds. Curr. Opin. Rheumatol. 2013;25:87–91. doi: 10.1097/BOR.0b013e32835b13b6. - DOI - PubMed
    1. Isogai S, Horiguchi M, Weinstein BM. The vascular anatomy of the developing zebrafish: An atlas of embryonic and early larval development. Dev. Biol. 2001;230:278–301. doi: 10.1006/dbio.2000.9995. - DOI - PubMed
    1. Huang C, Lawson ND, Weinstein BM, Johnson SL. reg6 is required for branching morphogenesis during blood vessel regeneration in zebrafish caudal fins. Dev. Biol. 2003;264:263–274. doi: 10.1016/j.ydbio.2003.08.016. - DOI - PMC - PubMed